In vitro and in vivo evaluation of an innocuous drug cocktail to improve the quality of folic acid targeted nuclear imaging in preclinical research

Molecular Pharmaceutics

Volumn 10, Issue 3, 2013, Pages 967-974

  Müller, Cristina ^a   Reber, Josefine ^a   Schlup, Claudia ^a   Leamon, Christopher P ^b   Schibli, Roger ^a,c  

^a ETH Zurich   (Switzerland)

^b Endocyte Inc   (United States)

^c ETH ZURICH   (Switzerland)

Author keywords

folate receptor targeting; kidney; pemetrexed; SPECT; thymidine

Indexed keywords

CAS 50 89 5; FOLATE RECEPTOR; FOLIC ACID; PEMETREXED; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UTERINE CERVIX CARCINOMA;

EID: 84874628244     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300428p     Document Type: Article

References (36)

1. Low, P. S.; Kularatne, S. A. Folate-targeted therapeutic and imaging agents for cancer Curr. Opin. Chem. Biol. 2009, 13, 256-62
2. Xia, W.; Hilgenbrink, A. R.; Matteson, E. L.; Lockwood, M. B.; Cheng, J. X.; Low, P. S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages Blood 2009, 113, 438-46
3. Hilgenbrink, A. R.; Low, P. S. Folate receptor-mediated drug targeting: From therapeutics to diagnostics J. Pharm. Sci. 2005, 94, 2135-2146
4. Low, P. S.; Henne, W. A.; Doorneweerd, D. D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases Acc. Chem. Res. 2008, 41, 120-9
5. Ke, C. Y.; Mathias, C. J.; Green, M. A. Folate-receptor-targeted radionuclide imaging agents Adv. Drug Delivery Rev. 2004, 56, 1143-1160
6. Sega, E. I.; Low, P. S. Tumor detection using folate receptor-targeted imaging agents Cancer Metastasis Rev. 2008, 27, 655-64
7. Müller, C.; Schibli, R. Folic acid conjugates for nuclear imaging of folate receptor-positive cancer J. Nucl. Med. 2011, 52, 1-4
8. Müller, C. Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation Curr. Pharm. Des. 2012, 18, 1058-1083
9. Sandoval, R. M.; Kennedy, M. D.; Low, P. S.; Molitoris, B. A. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy Am. J. Physiol. 2004, 287, C517-C526
10. Birn, H.; Spiegelstein, O.; Christensen, E. I.; Finnell, R. H. Renal tubular reabsorption of folate mediated by folate binding protein 1 J. Am. Soc. Nephrol. 2005, 16, 608-615
11. 67Ga-DOTA-Bz-folate-investigations of methods to improve the tissue distribution of radiofolates Nucl. Med. Biol. 2011, 38, 715-723
12. 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer J. Nucl. Med. 2008, 49 (4) 623-629
13. 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages Mol. Pharmaceutics 2012, 9, 1435-1440
14. Piscaer, T. M.; Muller, C.; Mindt, T. L.; Lubberts, E.; Verhaar, J. A.; Krenning, E. P.; Schibli, R.; De Jong, M.; Weinans, H. Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography Arthritis Rheum. 2011, 63, 1898-1907
15. Müller, C.; Brühlmeier, M.; Schubiger, A. P.; Schibli, R. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo J. Nucl. Med. 2006, 47, 2057-2064
16. Müller, C.; Mindt, T. L.; de Jong, M.; Schibli, R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 938-946
17. Müller, C.; Reddy, J. A.; Leamon, C. P.; Schibli, R. Effects of the Antifolates Pemetrexed and CB3717 on the Tissue Distribution of Tc-99m-EC20 in Xenografted and Syngeneic Tumor-Bearing Mice Mol. Pharmaceutics 2010, 7, 597-604
18. Chattopadhyay, S.; Moran, R. G.; Goldman, I. D. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther. 2007, 6, 404-417
19. Shih, C.; Chen, V. J.; Gossett, L. S.; Gates, S. B.; MacKellar, W. C.; Habeck, L. L.; Shackelford, K. A.; Mendelsohn, L. G.; Soose, D. J.; Patel, V. F.; Andis, S. L.; Bewley, J. R.; Rayl, E. A.; Moroson, B. A.; Beardsley, G. P.; Kohler, W.; Ratnam, M.; Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes Cancer Res. 1997, 57, 1116-1123
20. 11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337 J. Natl. Cancer Inst. 2003, 95, 675-682
21. Howell, S. B.; Herbst, K.; Boss, G. R.; Frei, E., 3rd Thymidine requirements for the rescue of patients treated with high-dose methotrexate Cancer Res. 1980, 40, 1824-1829
22. Grem, J. L.; King, S. A.; Sorensen, J. M.; Christian, M. C. Clinical use of thymidine as a rescue agent from methotrexate toxicity Invest. New Drugs 1991, 9, 281-290
23. Widemann, B. C.; Balis, F. M.; Kim, A.; Boron, M.; Jayaprakash, N.; Shalabi, A.; O'Brien, M.; Eby, M.; Cole, D. E.; Murphy, R. F.; Fox, E.; Ivy, P.; Adamson, P. C. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome J. Clin. Oncol. 2010, 28, 3979-3986
24. Castro, M. Thymidine rescue: An antidote for pemetrexed-related toxicity in the setting of acute renal failure J. Clin. Oncol. 2003, 21, 4066
25. Schultz, R. M.; Patel, V. F.; Worzalla, J. F.; Shih, C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514 Anticancer Res. 1999, 19, 437-443
26. Smith, P. G.; Marshman, E.; Calvert, A. H.; Newell, D. R.; Curtin, N. J. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines Semin. Oncol. 1999, 26, 63-67
27. Smith, P. G.; Marshman, E.; Newell, D. R.; Curtin, N. J. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport Br. J. Cancer 2000, 82, 924-930
28. Ladino, C. A.; Chari, R. V. J.; Bourret, L. A.; Kedersha, N. L.; Goldmacher, V. S. Folate-maytansinoids: target-selective drugs of low molecular weight Int. J. Cancer 1997, 73, 859-864
29. Chattopadhyay, S.; Zhao, R.; Tsai, E.; Schramm, V. L.; Goldman, I. D. The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity Mol. Cancer Ther. 2006, 5, 2549-2555
30. 99mTc- radiofolate uptake in tumors and kidneys Nucl. Med. Biol. 2007, 34, 603-608
31. Muhsin, M.; Gricks, C.; Kirkpatrick, P. Pemetrexed disodium Nat. Rev. Drug Discovery 2004, 3, 825-826
32. Curtin, N. J.; Hughes, A. N. Pemetrexed disodium, a novel antifolate with multiple targets Lancet Oncol. 2001, 2, 298-306
33. Morotti, M.; Valenzano Menada, M.; Venturini, P. L.; Mammoliti, S.; Ferrero, S. Pemetrexed disodium in ovarian cancer treatment Expert Opin. Invest. Drugs 2012, 21, 437-449
34. Simon, M.; Blatter, J.; Granzow, C. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation Anticancer Res. 2007, 27, 769-773
35. Van der Wilt, C. L.; Backus, H. H.; Smid, K.; Comijn, L.; Veerman, G.; Wouters, D.; Voorn, D. A.; Priest, D. G.; Bunni, M. A.; Mitchell, F.; Jackman, A. L.; Jansen, G.; Peters, G. J. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors Cancer Res. 2001, 61, 3675-3681
36. Kamb, A. What's wrong with our cancer models? Nat. Rev. Drug Discovery 2005, 4, 161-165